Anti-C1q antibodies were present among 74.3% of patients with immunoglobulin G4-related disease. Anti-C1q antibodies are highly prevalent among patients with immunoglobulin G4-related disease (IgG4-RD ...
Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammation Leuven, Belgium – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results